Submission of Outcome of Board Meeting of the Company held on Saturday, 14th February, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Nexus Surgical And Medicare Ltd approved the unaaudited financial results for the quarter and nine months ended December 31, 2025 at a meeting held on February 14, 2026. For Q3 FY26, total income surged to Rs. 293.65 lakhs from Rs. 148.39 lakhs in Q3 FY25, nearly doubling year-on-year, while profit after tax rose about 50% to Rs. 17.01 lakhs (from Rs. 11.36 lakhs). For the nine-month period, total income grew to Rs. 582.75 lakhs from Rs. 423.91 lakhs, a rise of roughly 37%, and profit after tax increased to Rs. 49.62 lakhs from Rs. 40.91 lakhs. Basic EPS for 9M FY26 stood at Rs. 0.91 versus Rs. 0.75 in the prior year period. The statutory auditor issued a clean limited review report with no qualifications or adverse comments.
Strong top-line and profit growth in Q3 signals improving business momentum, likely positive for the stock. However, the company continues to carry negative other equity of Rs. (440.83) lakhs, indicating accumulated losses that remain a long-term concern for shareholders.